• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    SARS-CoV-2 R&D: Is It Over?

    Sustainability: A New Threat or Opportunity for CDMOs?

    Advanced Therapy Manufacturing

    Advanced Therapy Packaging Trends

    CEO Spotlight: Darren Head
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Piramal Pharma Solutions New API Plant in Canada Now Online

    MG America Appoints Claudio Radossi as President

    Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY

    Sartorius Expands Manufacturing Site in Tunisia

    BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Piramal Pharma Solutions New API Plant in Canada Now Online

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY

    Grand Opening of Kodiak Sciences’ Bioconjugation Facility

    Vertex Expands Cell and Gene Therapy Footprint
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    Royalty Pharma and Jefferies Invest $111M in ApiJect

    Cryoport Acquires Cell&Co BioServices for €6.2M

    Challenges of Developing Large Volume Drug/Device Combination Products for Parenteral SC Delivery

    Yourway Adds Capacity for Controlled Ambient Storage
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Selecting a CMO Partner for Sterile Injectable Manufacturing

    BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment

    WCG Appoints Sam Srivastava CEO

    AffyXell Expands Manufacturing Partnership with GenScript ProBio

    ABL and Odimma Therapeutics Enter Development Agreement
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA Inspection Trends Update

    Phase-Appropriate cGMP Considerations for Cell and Gene Therapy

    Sustainability: A New Threat or Opportunity for CDMOs?

    In Pursuit of Sustainability: How the Biopharma Industry Can Contribute

    Conducting Clinical Trials During the Pandemic: What Did We Learn?
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Aphena Pharma Solutions

    CMC Pharmaceuticals

    Biosynth Carbosynth

    Baxter BioPharma Solutions
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Aphena Pharma Solutions

    CMC Pharmaceuticals

    Biosynth Carbosynth

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    The Need for Standards in Cell and Gene Therapy

    Identifying and understanding the areas with the greatest need for standardization to help the cell and gene industry progress.

    The Need for Standards in Cell and Gene Therapy
    The Need for Standards in Cell and Gene Therapy
    Figure 1. Contributors to report on needed standards.
    The Need for Standards in Cell and Gene Therapy
    Figure 2 Needed Standards in Regenerative Medicine by Functional Area
    The Need for Standards in Cell and Gene Therapy
    The Need for Standards in Cell and Gene Therapy
    Figure 3. Impact versus Urgency Prioritization of Needed Standards Areas
    Robert Shaw, Executive Director, Standards Coordinating Body for Regenerative Medicine06.07.21
    The regenerative medicine industry is developing life changing therapies for many diseases and conditions, which to date, have not had any viable treatments. In addition, novel approaches for using cells for tissue engineering, along with in vitro cell and organ models are allowing researchers and clinicians to approach diseases and disease modeling in very different ways. As the technologies for developing these cell-based therapies and models are new as well, the Standards Coordinating Body for Regenerative Medicine (SCB) seeks to identify and understand the areas with the greatest need for standardization to help the industry progress as quickly—and safely—as possible. In this article, I outline our recently published document entitled: “Community Perspectives: Needed Standards in Regenerative Medicine.” 

    Accelerating Standards Development
    The primary goal of SCB is to accelerate standards development. Patients are counting on the industry to bring these new, novel and innovative therapies and products as quickly as they can.

    In the past, standards development has been seen to take years. This can be attributed to the passive process of standards work which is primarily based on volunteer contributors from the industry. SCB makes accelerated standards advancements possible by focusing on the high priority/high impact standards and actively facilitating the process. Without a coordinating body like SCB, these pre-development steps can take up to six years; with SCB’s support, these steps take as little as six months to one year.

    The data in support of the need for regenerative medicine and cell and gene therapies is clear. The Alliance for Regenerative Medicine identified in their State of the Industry (SOTI, January 2021) report, there are more than 1220 clinical trials underway, 152 in Phase III, and nearly $20 billion dollars was raised in 2020. Along with this intense interest and activity, major questions and themes for the industry remain including: 
    • How do we address commercialization/industrialization (scale-up or out) of cell and gene therapies?
    • How do we address costs?
    • How do we accelerate innovation to help support these goals?
    • How do developers of therapeutics most efficiently address tech transfer as many products are being manufactured in CDMOs?

    The 21st Century Cures Act—signed into law on December 2016—directed the U.S. Food and Drug Administration (FDA) to accelerate medical product development through the advancement of standards. SCB has been supporting this need by identifying existing and in-development standards relevant to regenerative medicine.

    Regenerative medicine has relatively few existing standards compared with more mature medical fields, leaving researchers and manufacturers to solve complex challenges of clinical translation and scaling of commercial products independently. Furthermore, regenerative medicine products are highly personalized and are often made of dynamic, living cells, which creates unique difficulties with establishing common practices for comparing test results and ensuring consistent product quality and safety.

    Beginning in 2018, SCB gathered feedback and input from more than 250 regenerative medicine stakeholders (Figure 1) for the “Needed Standards Report” through expert interviews, a community-wide survey, and community prioritization exercises at several workshops.  

    This report compiled the information provided by the industry and stakeholders and segmented data into the sectors of regenerative medicine that each area was most relevant to:
    • Cell therapy: Products made from living, whole cells that are injected into a patient in order to treat a disease.
    • Gene therapy: Products that aim to correct or compensate for defective versions of genes by delivering a healthy copy into patients' cells.
    • Tissue engineering: Products made from scaffolds, cells, and/or biologically active molecules to create new, functional tissue or whole organs.

    In addition, detailed standards were assigned to appropriate functional areas where they would be most applicable.
    • Bioprocessing and Production: The design and development of processes, materials, and equipment for manufacturing products from raw/ancillary biological materials (e.g., the characterization of starting materials such as cells, gene therapy vectors, and biomaterials).
    • Analytics and Testing Methods: The tools and methods used to detect, measure, and/or monitor the properties and state of regenerative medicine product components.
    • Product Quality and Characterization: The measurements and guidelines needed to convey well-defined quality attributes of materials used in regenerative medicine therapies and provide a clear understanding of their intended use.
    • Logistics and Compliance: The processes and protocols surrounding the coordinated collection, manufacturing, and administration of cells and other therapy products across the supply chain.
    • Preclinical Studies: The testing of a drug, procedure, or other medical treatment in animals before clinical trials in humans can be started.
    • Clinical Trials: The research studies that determine whether a regenerative medicine strategy, treatment, or device is safe and effective for human use.

    Many of the standards needs listed in the report describe challenges common to multiple regenerative medicine sectors. All of the standards needs in the cell therapy section will relate to common regenerative medicine process or quality concerns and are therefore also applicable to the tissue engineering and/or gene therapy sectors.

    The insights gleaned from the research identified 44 areas identified and prioritized by the regenerative medicine community where standards could yield significant benefits to the field (Figure 2).
    Additionally, we wanted to understand the relative priority of each of these needs based on their potential impact to the field and the urgency with which a need must be addressed:
    • Impact is defined as the difference a needed standard could have on the regenerative medicine community, product development, and ultimately on patient care. This includes the   extent to which addressing this need could improve the safety/quality, and/or accelerate the time to market or development of a product, lower the cost to develop products, and improve patient access and care.
    • Urgency refers to the difference that acting now versus later could make to the quality and safety of regenerative medicine products.  (We use a 5-year time horizon as reference)

    The top five areas of need, which are revisited annually in light of industry dynamics and trends are defined as follows (“G” refers to gene therapy; “C” cell therapy; “T” tissue engineering):
    • G4 Viral Vector Gene Quantification
    • G1 Framework for Gene Delivery Methods & Gene Editing Tools
    • C12 Test Methods to Measure Sterility, Mycoplasma, and Adventitious Agents
    • T1 Characterization of Scaffold Materials
    • C22 Transportation Standards for Regenerative Medicine Products

    With the progress of gene therapy and gene-modified therapeutic products, it should be no surprise that Viral Vector Gene Quantification and Gene Delivery Methods/Gene Editing tools were identified as most impactful and urgent. The industry has struggled generally with assessment of sterility, mycoplasma and adventitious agents due to the nature of cell-based products. 

    Additionally, for autologous therapies where the time between final dose preparation and administration is generally much less than 14 days, standard USP sterility tests cannot be employed. Rapid methods have the potential to have great impact here and the National Institute of Standards and Technology (NIST) has recently established a Rapid Microbial Testing Methods consortium to address these very issues ( https://www.nist.gov/programs-projects/nist-rapid-microbial-testing-methods-consortium). The characterization of scaffold materials in tissue engineered products is not surprising given the complexities of the materials and the structures produced in this area. Transportation standards for Regenerative Medicine products are becoming more and more important especially with patient-specific therapies being approved (Figure 3).

    Key Themes from the Segments Cell Therapy
    • Many of the needs in this sector are interrelated with gene therapy and tissue engineering.
    • A core challenge of cell therapy is cell characterization—defining critical quality attributes (CQAs) and optimal testing methods to ensure that cell therapy products are safe and effective.
    • Several other standards needs relate to better understanding individual areas of CQAs: identity, cell counting, and viability.
    • Other key challenges include mitigating the potentially harmful effects of foreign agents in cell therapy products (e.g., microbes, particulates) and working around short product shelf lives.
    • Criteria for method selection (i.e., which assay to use and when to use it) will help improve efficiency and consistency in cell therapy production.

    Gene Therapy
    • Delivery of appropriate doses of vectors to patients is a foundational challenge that could be addressed through vector quantification standards.
    • The factors that cause adverse reactions in gene therapy patients (e.g., immune response to T-cell therapy products or complications from replication-competent retroviruses [RCRs]) must be better understood.
    • The sector also needs robust best practices for gene editing tool selection and use to support overall safety and effectiveness of products

    Tissue Engineering
    • Researchers and product developers are working to create tissue engineering scaffolds with consistent properties and long-term integrity. Standards can help with this challenge.
    • The tissue engineering sector currently lacks specific standards to define optimal testing methods and fit-for-purpose measurements, particularly in the Bioprocessing and Production and Clinical Trials functional areas.

    The Way Forward
    The top areas of need as identified in the Needed Standards report will be assessed for Feasibility for standards development.  Feasibility is an objective assessment by which Tier 1 (Technical, Economic and Operational aspects are considered) and Tier 2 (Legal, Resource (SDO and SME) and Schedule) parameters are reviewed with stakeholders. This determination helps us understand whether a particular area is ready for proceed into the standards development process. 

    The industry faces many challenges in cost, time, and efficiency. Virtually every product can benefit from the development of standards in areas that are common across platforms (e.g. Ancillary Materials, Cell Viability, Cell Counting) and aid in both process development and characterization in addition to easing regulatory review burdens. SCB is an organization focused on continuing to accelerate the standards development process, inform and educate the field by making information as readily available as possible, and is looking to help industry implement standards in the most efficient and appropriate ways.

    Development of standards can help address many challenges the industry faces. In order to support the growth of this field and the continued success of emerging therapies, the regenerative medicine community must advance new standards targeted at the field’s most pressing needs. The Needed Standards Report is intended to help identify these areas and focus efforts to support efficient, and scalable practices and reduce the burden on companies seeking regulatory approval for their products. 


    Bob Shaw is the executive director of the Standards Coordinating Body (SCB). Bob’s past experience spans nearly 30 years of technical, operational, strategic, and commercial development in the regenerative medicine and biotechnology fields. Prior to joining SCB, he served as Vice President of Thermo Fisher Scientific, where he implemented a number of innovations to drive growth and expansion, including strategic processes to improve the structure and function of their Field Scientist and Program Management functions.
    Related Searches
    • Biologics, Proteins, Vaccines
    • Drug Development

    Related Content

      Trending
      • Royalty Pharma and Jefferies Invest $111M in ApiJect
      • Cellipont Bioservices Expands Cell Therapy Facility | Contract Pharma
      • Piramal Pharma Solutions New API Plant In Canada Now Online | Contract Pharma
      • Biopharma Manufacturing Facility Construction | Contract Pharma
      • Next-Gen Lab Services | Contract Pharma
      Breaking News
      • Piramal Pharma Solutions New API Plant in Canada Now Online
      • MG America Appoints Claudio Radossi as President
      • Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
      • Sartorius Expands Manufacturing Site in Tunisia
      • BioMoti Partners with Pharma Company to Develop Ovarian Cancer Treatment
      View Breaking News >
      CURRENT ISSUE

      May 2022

      • Sustainability and the Biopharma Industry
      • Contract Manufacturing During COVID
      • Orphan Drugs in the United States
      • CEO Spotlight: Peter DeYoung
      • CEO Spotlight: Darren Head
      • Advanced Therapy Packaging Trends
      • Advanced Therapy Manufacturing
      • Sustainability: A New Threat or Opportunity for CDMOs?
      • SARS-CoV-2 R&D

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      GOED Creates Infographic Highlighting Omega-3 Health Claims Approved in Europe
      Kyowa Hakko Appoints Dr. Colin Hill to Immuse Scientific Advisory Board
      Expert Consensus Statement: Diet is Best Primary Intervention to Achieve Diabetes Remission
      Coatings World

      Latest Breaking News From Coatings World

      What Are You Reading?
      Teknos Receives EcoVadis Gold Medal for Sustainability Performance
      AkzoNobel and Partners Team Up to Hack Carbon Reduction Challenges
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      MPO's Most-Read Stories This Week—May 21
      Iterative Scopes Expands its Senior Leadership Team
      Viz.ai Raises $100 Million in Series D Funding
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Piramal Pharma Solutions New API Plant in Canada Now Online
      MG America Appoints Claudio Radossi as President
      Catalent Invests $175M to Expand Mfg. Capabilities at Winchester, KY
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      Authentic Beauty Concept Launches Second-Generation ‘Refill Bar’
      HASK Beauty Enters Exclusive Partnership with Amazon
      Garance Doré Launches Made in France Skincare Line
      Happi

      Latest Breaking News From Happi

      P&G Closes HQ Due To Security Threat, Launches New Hair Care Line
      SPF Setting Spray, Lip Contour and Knotless Braids Are Hot Trends: Spate
      Nutrafol Launches Collagen Infusion
      Ink World

      Latest Breaking News From Ink World

      Weekly Recap: Zeller+Gmelin, Sun Chemical and Kornit Top This Week’s News
      Nazdar Celebrates 100 Years with a New Look
      hubergroup Chemicals Exhibits at Paint India for First Time
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Brook + Whittle's new acquisition, SunDance goes to HP and more
      Specialty announces move to new facility
      Mark Andy hosts dealer's open house in Warsaw
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Weekly Recap: Kimberly-Clark to Expand Diaper, Wipes Production in Brazil; The Honest Company to Sell Diapers, Wipes at Walmart & More
      3M to Expand in Nebraska
      Nicely Offers Nonwoven Slitters, Winders
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      ODT's Most Read Stories This Week—May 21
      FDA Clears Anika Therapeutics' X-Twist Knotless Fixation System
      Paragon 28 Rolls Out TenoTac 2.0 Hammertoe and Soft Tissue Repair
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Weekly Recap: Graphene Flagship, Japan Display and LG Display Top This Week’s Stories
      Evonik Launches New Processing Aids for PV Wafer Cutting
      NREL Creates Highest Efficiency 1-Sun Solar Cell

      Copyright © 2022 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login